Castle Biosciences (CSTL) Stock Price
Castle Biosciences Price
Revenue has compounded at 52.0% per year over the past 8 years to 344.14 M USD. Castle Biosciences's net margin stands at -7.0%, up from -33.3% several years earlier. Analysts set a median price target of 40.00 USD, implying 11.7% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 97% above its 52-week low.
Castle Biosciences stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Castle Biosciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Castle Biosciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Castle Biosciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Castle Biosciences Price |
|---|---|
| 9/25/2026 | 35.81 USD |
| 9/24/2026 | 35.81 USD |
| 9/23/2026 | 34.88 USD |
| 9/22/2026 | 34.71 USD |
| 9/21/2026 | 35.37 USD |
| 9/18/2026 | 36.20 USD |
| 9/17/2026 | 36.78 USD |
| 9/16/2026 | 35.94 USD |
| 9/15/2026 | 34.85 USD |
| 9/14/2026 | 33.44 USD |
| 9/13/2026 | 32.70 USD |
| 9/11/2026 | 32.06 USD |
| 9/10/2026 | 32.32 USD |
| 9/9/2026 | 32.31 USD |
| 9/8/2026 | 32.67 USD |
| 9/4/2026 | 32.91 USD |
| 9/3/2026 | 32.65 USD |
| 9/2/2026 | 33.42 USD |
| 9/1/2026 | 33.44 USD |
| 8/31/2026 | 33.03 USD |
| 8/30/2026 | 32.81 USD |
| 8/28/2026 | 33.01 USD |
| 8/27/2026 | 34.68 USD |
| 8/26/2026 | 34.08 USD |
| 8/25/2026 | 35.00 USD |
| 8/24/2026 | 34.15 USD |
| 8/21/2026 | 34.20 USD |
| 8/20/2026 | 32.93 USD |
| 8/19/2026 | 31.01 USD |
| 8/18/2026 | 28.88 USD |
Castle Biosciences Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Castle Biosciences Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.00 | 22.00 | 51.00 | 62.00 | 94.00 | 137.00 | 219.00 | 332.00 | 344.00 | 372.00 | 410.00 | 461.00 | 498.00 | 541.00 |
| – | 69.23 | 131.82 | 21.57 | 51.61 | 45.74 | 59.85 | 51.60 | 3.61 | 8.14 | 10.22 | 12.44 | 8.03 | 8.63 |
| 61.54 | 77.27 | 86.27 | 83.87 | 82.98 | 76.64 | 79.45 | 81.63 | 79.36 | 79.36 | 79.36 | 79.36 | 79.36 | 79.36 |
| 8.00 | 17.00 | 44.00 | 52.00 | 78.00 | 105.00 | 174.00 | 271.00 | 273.00 | 295.22 | 325.38 | 365.85 | 395.22 | 429.34 |
| -10.00 | -4.00 | 7.00 | -6.00 | -40.00 | -72.00 | -67.00 | 8.00 | -42.00 | -36.00 | -28.00 | -6.00 | 17.00 | 32.00 |
| -76.92 | -18.18 | 13.73 | -9.68 | -42.55 | -52.55 | -30.59 | 2.41 | -12.21 | -9.68 | -6.83 | -1.30 | 3.41 | 5.91 |
| -12.00 | -6.00 | 5.00 | -10.00 | -31.00 | -67.00 | -57.00 | 18.00 | -24.00 | -37.00 | -28.00 | -10.00 | 15.00 | 29.00 |
| – | -50.00 | -183.33 | -300.00 | 210.00 | 116.13 | -14.93 | -131.58 | -233.33 | 54.17 | -24.32 | -64.29 | -250.00 | 93.33 |
| 9.78 | 10.65 | 18.60 | 20.83 | 25.33 | 26.40 | 27.14 | 30.20 | 29.33 | 29.33 | 29.33 | 29.33 | 29.33 | 29.33 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Castle Biosciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Castle Biosciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Castle Biosciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Castle Biosciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Castle Biosciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Castle Biosciences stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Castle Biosciences Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Castle Biosciences business model & stock analysis
Castle Biosciences SWOT Analysis
Strengths
Castle Biosciences Inc is a prominent player in the biotechnology industry, known for their innovative products and services.
The company has a strong portfolio of advanced diagnostic tests for skin cancer and other dermatologic conditions, offering reliable and accurate results.
Castle Biosciences Inc has established a solid reputation for their expertise and comprehensive understanding of personalized medicine, which further enhances their market position.
The company's dedicated and skilled team of professionals is a key strength, ensuring high-quality research, development, and customer support.
Weaknesses
One potential weakness for Castle Biosciences Inc is their reliance on a limited range of diagnostic tests. Diversifying their product offerings could help mitigate this risk.
The company may face challenges in terms of regulatory compliance and obtaining necessary approvals for their diagnostic tests, which could result in delays or limitations on market entry.
Castle Biosciences Inc may also be more vulnerable to competition from larger, established biotechnology companies that have greater resources and market presence.
Opportunities
There is a growing demand for personalized medicine and advanced diagnostics, presenting significant opportunities for Castle Biosciences Inc to expand their market share.
The company can explore collaborations and partnerships with healthcare providers and pharmaceutical companies to leverage their expertise and reach a wider customer base.
Expanding into international markets could also be a viable opportunity for Castle Biosciences Inc to broaden their customer reach and increase revenue.
Threats
Competition in the biotechnology industry is intense, with new entrants and established players constantly emerging. Castle Biosciences Inc must stay vigilant and continuously innovate to stay ahead.
Evolving healthcare regulations and policies can pose challenges for Castle Biosciences Inc, as compliance and adherence to these regulations may require significant resources and adaptations.
Market uncertainties and economic fluctuations can also impact the demand for diagnostic tests, making it essential for Castle Biosciences Inc to maintain financial stability and diversify revenue streams.
Castle Biosciences Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Castle Biosciences Segments
Castle Biosciences Revenue by Segment (1/2)
Max
Details
Castle Biosciences Revenue by Segment (2/2)
Max
Details
Castle Biosciences Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Castle Biosciences historical P/E ratio, EBIT multiple, and P/S ratio
Castle Biosciences annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Castle Biosciences's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Castle Biosciences's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Castle Biosciences's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Castle Biosciences shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Castle Biosciences forecasts and price targets in September 2026
Analyst Price Targets 2026Castle Biosciences Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/3/2026 | Maintained | Buy | 49 | |
| 5/13/2026 | Maintained | Buy | 49 | |
| 5/7/2026 | Maintained | Outperform | 65 | |
| 4/20/2026 | Maintained | Buy | 63 | |
| 2/27/2026 | Maintained | Outperform | 65 | |
| 1/26/2026 | Maintained | Buy | 39 | |
| 1/12/2026 | Maintained | Buy | – | |
| 1/5/2026 | Maintained | Buy | 39 | |
| 12/22/2025 | Maintained | Buy | 63 | |
| 12/12/2025 | Maintained | Buy | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Castle Biosciences Earnings Calls
Castle Biosciences Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/2/2026 | -0.38USD | - | 92.26 MUSD | - | 2026 Q3 |
| 7/30/2026 | -0.41USD | -0.07USD | 86.23 MUSD | - | 2026 Q2 |
| 5/6/2026 | -0.49USD | -0.49USD | 79.23 MUSD | - | 2026 Q1 |
| 2/26/2026 | -0.23USD | -0.08USD | 79.89 MUSD | - | 2025 Q4 |
| 11/3/2025 | -0.34USD | -0.02USD | 80.38 MUSD | - | 2025 Q3 |
| 8/4/2025 | -0.51USD | 0.15USD | 68.00 MUSD | - | 2025 Q2 |
| 5/5/2025 | -0.08USD | -0.90USD | 80.31 MUSD | - | 2025 Q1 |
| 2/27/2025 | -0.04USD | 0.32USD | 83.89 MUSD | - | 2024 Q4 |
| 11/4/2024 | -0.06USD | 0.08USD | 80.58 MUSD | - | 2024 Q3 |
| 8/5/2024 | -0.27USD | 0.31USD | 69.34 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Castle Biosciences stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Castle Biosciences shareholder structure
| % | Name |
|---|---|
10.21907% | |
9.44959% | |
6.06330% | |
4.62584% | |
4.03399% | |
3.56205% |
Castle Biosciences Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
12.30% | SEC ↗ | |
10.44% | SEC ↗ | |
9.30% | SEC ↗ | |
8.20% | SEC ↗ | |
8.05% | SEC ↗ | |
7.30% | SEC ↗ | |
7.10% | SEC ↗ | |
6.62% | SEC ↗ | |
6.00% | SEC ↗ | |
6.00% | SEC ↗ |
Castle Biosciences Executives and Management Board
11 members · avg. age 62 · 36 % women
Mr. Derek Maetzold (63)
President, Chief Executive Officer, Founder, Director · since 2007
6.94 M USD
Management
Ms. Kristen Oelschlager (57)
Chief Operating Officer
Mr. Tobin Juvenal (65)
Chief Commercial Officer
Mr. Frank Stokes (55)
Chief Financial Officer
Board of Directors
Mr. Rodney Cotton (65)
Independent Director
Ms. Tiffany Olson (65)
Independent Director
Mr. Daniel Bradbury (64)
Independent Chairman of the Board
Mr. G. Bradley Cole (69)
Independent Director
Mr. Miles Harrison (60)
Independent Director
Ms. Kimberlee Caple (63)
Independent Director
Frequently asked questions about Castle Biosciences
The business model of Castle Biosciences Inc revolves around providing diagnostic and prognostic solutions for patients with skin and other cancers. By leveraging advanced genomic technology, the company offers diagnostic tests that assess the risk, recurrence, and progression of various cancers. Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that aid in personalized treatment decisions for cancer patients. With a patient-centric approach, the company aims to improve patient outcomes and contribute to the advancement of precision medicine. Castle Biosciences Inc is dedicated to revolutionizing cancer management through innovative diagnostics.
Castle Biosciences Inc is primarily active in the healthcare industry, specifically in the field of precision medicine. The company specializes in developing and commercializing molecular diagnostics tests that provide personalized genomic information to aid in the diagnosis and treatment of various types of cancer. Castle Biosciences Inc's innovative solutions help healthcare professionals make informed decisions about patient care by assessing the likelihood of disease recurrence and determining optimal treatment plans. With a focus on improving patient outcomes, Castle Biosciences Inc is dedicated to advancing precision medicine in oncology.
The main competitors of Castle Biosciences Inc in the market are Myriad Genetics, Genomic Health, and NanoString Technologies.
Castle Biosciences Inc is a leading precision oncology company that specializes in molecular diagnostics. Established in 2008, the company is dedicated to providing personalized medicine solutions for patients with challenging cancers. With a focus on dermatologic cancers, Castle Biosciences utilizes advanced genomic and proteomic technology to develop innovative diagnostic tests. Their flagship product, DecisionDx-Melanoma, is a powerful tool that assesses the risk and prognosis of melanoma patients. Castle Biosciences Inc has a strong commitment to research, collaboration, and improving patient outcomes. With their cutting-edge technology and expertise, the company continues to revolutionize cancer diagnostics and treatment strategies.
Castle Biosciences Inc has achieved several significant milestones since its inception. The company pioneered the development of DecisionDx®-Melanoma, a groundbreaking gene expression profile test, which has revolutionized the management of melanoma patients. Castle Biosciences Inc has also expanded its product portfolio with DecisionDx®-UM, a test for uveal melanoma, providing accurate prognostic information for physicians and patients. In addition, the company has received numerous awards and recognitions for its innovative approach to personalized medicine, further establishing its leadership in the field. Castle Biosciences Inc continues to drive advancements in genomic diagnostics, improving patient outcomes and transforming cancer care.
Castle Biosciences Inc is primarily present in the United States.
Castle Biosciences Inc represents values such as innovation, accuracy, and patient-centricity. With a strong corporate philosophy centered around precision medicine, the company utilizes advanced genomic technology to provide actionable, personalized information to aid healthcare decisions for patients with underserved cancers. Castle Biosciences Inc is committed to improving patient outcomes through its proprietary diagnostic tests that offer valuable insights into the individual biology of each patient. By combining science, research, and a patient-first approach, Castle Biosciences Inc strives to empower healthcare providers and patients with the necessary tools to make informed, targeted treatment decisions.
Analysts currently set an average price target of 39.00 USD for the Castle Biosciences stock (median: 40.00 USD), implying +8.9 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Castle Biosciences stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Castle Biosciences to generate revenue of 372.59 M USD and earnings per share of -1.27 USD.
Converted at the current exchange rate, the Castle Biosciences share trades at 31.42 EUR (35.81 USD).
The Castle Biosciences share (CSTL) is listed on 1 stock exchanges, including: NASDAQ (CSTL).
Castle Biosciences Inc is a biotechnology company that develops and distributes diagnostic tests and genetic analyses. The company is headquartered in Friendswood, Texas, USA and has been operating in the industry since 2007. The main task of Castle Biosciences is to develop clinically accurate prediction tools to assess the progression of tumors and consider them in patient treatment. For this purpose, the company has developed a range of test procedures based on a combination of genotyping, proteomics, and immuno-sensing methods. The key product of Castle Biosciences is the Prognostic Test, which provides an accurate assessment of the risk of skin cancer. The test uses molecular markers to predict the risk of melanoma or ocular melanoma and determine if therapy is necessary. Another product is DecisionDx-UM, a powerful diagnostic assay that aids in the prognosis of malignant uveal melanoma (UM). In combination with standardized clinical factors such as age, gender, and tumor size, DecisionDx-UM is an important indicator of disease progression as well as promising treatment approaches. Castle Biosciences offers a wide range of proteomic analyses tailored to the needs of the patient. These tests are used to estimate the risk of cancer and enable treating physicians to develop treatment and follow-up strategies. The company also conducts a number of research and development initiatives aimed at understanding the molecular basis of cancer and developing novel diagnostic tests and therapies. The goal is to make groundbreaking scientific discoveries to identify new and improved molecular markers that can be used to assess disease progression and the efficacy of therapies. Overall, Castle Biosciences provides an advanced and accurate platform for cancer diagnostics that can help patients and doctors make better-informed decisions. The company is dedicated to further exploring the molecular basis of cancer and developing more innovative diagnostic tools to improve patient care worldwide. In summary, the business model of Castle Biosciences is focused on the development and marketing of diagnostic tools for cancer treatment. The company offers a wide range of molecular, proteomic, and immuno-sensing analyses that enable accurate prognosis of tumor progression. The company also conducts extensive research and development initiatives to discover new molecular markers for the diagnosis and treatment of cancer.
The expected revenue of Castle Biosciences is 372.59 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Castle Biosciences is -37.14 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Castle Biosciences is currently -28.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Castle Biosciences stock.
The price-to-sales ratio (P/S) of Castle Biosciences is currently 2.82. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Castle Biosciences stock.
The Eulerpool Quality Score for Castle Biosciences is 2/10.
The ISIN of Castle Biosciences is US14843C1053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Castle Biosciences is A2PNH3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Castle Biosciences is CSTL. The ticker symbol is used to trade Castle Biosciences shares on the stock exchange.
Castle Biosciences paid dividends every year for the past 0 years.
Castle Biosciences is assigned to the 'Health' sector.
The dividends of Castle Biosciences are distributed in USD.
Castle Biosciences stock
Castle Biosciences Peer Group
Castle Biosciences Ticker
Castle Biosciences FIGI
All fundamentals and in-depth analysis of Castle Biosciences
Our stock analysis for Castle Biosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Castle Biosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.